Taiwan-based JBM Biotech (6827) announced on May 19, 2026, that its cell therapy product MPB-2354 (RegenTrace), developed using its proprietary nanoparticle technology platform, has won the top prize at an international innovation competition. The company's board has approved the establishment of a US subsidiary to support Phase 1/2a clinical trials of RegenTrace in the United States, targeting the multi-billion-dollar US market for critical limb ischemia (CLI).
CEO Wang Xianzhi stated that RegenTrace represents an innovative combination of nanotechnology and cell therapy. The company plans to launch a Series A fundraising round in the US this year, targeting $10 million, and commence Phase 1/2a clinical trials next year.
RegenTrace recently won first place in the Health Tech Pitch Category at the 2026 SelectUSA Investment Summit, becoming the gold medalist in the medical technology group. This achievement was supported by the Small and Medium Enterprise and Startup Administration of Taiwan's Ministry of Economic Affairs, which helped the company gain international recognition.
Source: Read the original report | Published: May 19, 2026